---
mi_id: MIPR-node_b3a6009
type: press_release
canonical_url: "https://www.pheonixresearch.com/food-beverages/health-wellness-functional-nutrition/press-release/supplement-contract-manufacturing-to-reach-usd-49-4-billion-by-2033-growing-slower-than-the-brands-it-supplies/"
md_url: "https://www.pheonixresearch.com/food-beverages/health-wellness-functional-nutrition/press-release/supplement-contract-manufacturing-to-reach-usd-49-4-billion-by-2033-growing-slower-than-the-brands-it-supplies.md"

schema:
  "@type": NewsArticle
  "@id": MIPR-node_b3a6009
  url: "https://www.pheonixresearch.com/food-beverages/health-wellness-functional-nutrition/press-release/supplement-contract-manufacturing-to-reach-usd-49-4-billion-by-2033-growing-slower-than-the-brands-it-supplies/"
  title: "Supplement Contract Manufacturing to Reach USD 49.4 Billion by 2033, Growing Slower Than the Brands It Supplies"
  description: "Supplement and nutraceutical contract manufacturing reaches USD 49.4bn by 2033 at 5.66%, below the 7.7% its brand customers grow at. Pheonix Research report."
  datePublished: "2026-11-21T13:24:08+00:00"
  dateModified: "2026-11-21T13:24:08+00:00"
  keywords:
    - supplement contract manufacturing
    - nutraceutical CDMO
    - dietary supplement manufacturing market
    - contract manufacturing forecast 2033
  isPartOf:
    - id: MISG-node_2e062fc
      type: CollectionPage
      url: "https://www.pheonixresearch.com/food-beverages/health-wellness-functional-nutrition/"
      name: "Health, Wellness & Functional Nutrition"
    - id: MIIN-node_b477d05
      type: CollectionPage
      url: "https://www.pheonixresearch.com/food-beverages/"
      name: "Food & Beverages"
    - id: MIWS-root
      type: WebSite
      url: "https://www.pheonixresearch.com/"
      name: Pheonix Research

acf:
  phoenix_meta_title: Supplement Contract Manufacturing to Reach USD 49.4 Billion by 2033
  phoenix_meta_description: "Supplement and nutraceutical contract manufacturing reaches USD 49.4bn by 2033 at 5.66%, below the 7.7% its brand customers grow at. Pheonix Research report."

global_schema:
  organization:
    "@id": MIWS-root#organization
    "@type": Organization
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  website:
    "@id": MIWS-root
    "@type": WebSite
    url: "https://www.pheonixresearch.com/"
    name: Pheonix Research
  api:
    "@id": MIWS-root#api
    "@type": WebAPI
    url: "https://www.pheonixresearch.com/"

graph:
  node_id: MIPR-node_b3a6009
  graph_node_endpoint: "https://graph.pheonixresearch.com/api/v1/query/live/node/MIPR-node_b3a6009"
  graph_snapshot: "https://graph.pheonixresearch.com/api/v1/read/live/graph"
  graph_exclusions: "https://graph.pheonixresearch.com/api/v1/read/live/exclusions"
  graph_meta: "https://graph.pheonixresearch.com/api/v1/read/live/meta"
  graph_bundle: "https://graph.pheonixresearch.com/api/v1/read/live/bundle"

discovery:
  discovery_json: "https://www.pheonixresearch.com/.well-known/pheonix-discovery.json"
  llms_txt: "https://www.pheonixresearch.com/llms.txt"
  sitemap: "https://www.pheonixresearch.com/sitemap.xml"
---
# Supplement Contract Manufacturing to Reach USD 49.4 Billion by 2033, Growing Slower Than the Brands It Supplies

**21 November 2026 — London.** The global market for contract development and manufacturing of dietary supplements and nutraceuticals will reach **USD 49,400.0 million by 2033**, up from **USD 31,800.0 million in 2025**, according to a new report from Pheonix Research. The forecast compound annual growth rate of **5.66 per cent** is materially below the 7.7 per cent at which the firm models the branded supplement market those manufacturers serve.

The gap is the report's central finding. Pheonix Research models global dietary supplement retail value at USD 189.4 billion in 2025 rising to USD 342.7 billion by 2033. On those two models, contract manufacturing represents **16.79 per cent of the consumer dollar in 2025 and 14.41 per cent in 2033** — meaning the manufacturing layer grows in absolute terms while losing share of the value chain it supplies.

## Why the manufacturer cannot hold the price

The report attributes the gap to the regulatory division of responsibility in the two largest Western markets. In the United States, a dietary supplement reaches market without pre-market approval, and the statement on its label is governed by 21 CFR 101.93. That rule requires notification within 30 days of first marketing by *"the manufacturer, packer, or distributor"*, requires the notification to name *"the dietary supplement (including brand name)"*, and requires the notifying firm to certify that it has substantiation that the statement is truthful and not misleading. No agency assessment of the claim takes place.

In the European Union, Directive 2002/46/EC harmonises the vitamins and minerals and the permitted sources that may be used in food supplements, and the Commission records that trade in substances not listed in Annex II has been prohibited since 1 August 2005. The same Directive never set the quantities. The Commission states that despite extensive consultation, *"no proposal has yet been presented due to the complex nature of the issue and the divergent views that were expressed."*

"The manufacturer carries the cost of proof and owns neither the claim nor the dose," the report argues. "The claim is the asset that carries the retail premium, and it moves to another supplier with the label artwork. Nothing in the plant has to be re-registered for that to happen."

## Three quarters of the growth is volume

Finished dose volume rises from **412.0 billion units in 2025 to 585.0 billion in 2033**, a compound rate of **4.48 per cent**. Realised revenue per thousand doses rises from **USD 77.18 to USD 84.44**, or **1.13 per cent a year**. Of the **USD 17,600.0 million** of value added across the forecast, **USD 13,352.1 million (75.9 per cent) is more volume**, **USD 2,991.1 million (17.0 per cent) is a higher price per dose**, and USD 1,256.0 million (7.1 per cent) is the interaction between the two.

## What the disclosures show

Two manufacturers disclose enough to be checked against the model. **Aenova Group** reported revenue of **EUR 882 million** in 2025 with adjusted EBITDA of **EUR 165 million** — an 18.71 per cent margin — described as its highest earnings to date and its fourth consecutive year of revenue growth. **Siegfried Holding AG** reported net sales of **CHF 1,327.8 million**, up 2.6 per cent in Swiss francs and 4.3 per cent at constant exchange rates, with core EBITDA of CHF 312.3 million at a 23.5 per cent margin, and capital expenditure of CHF 231.5 million, up 28.0 per cent, against flat headcount of 3,891 full-time equivalents.

The report reads those disclosures as evidence of a sector competing on service reliability and capability rather than on price, and notes that Aenova's stated strategic platforms — sterile injectables, high potent and complex solids, large-volume oral solid dose and softgel — are predominantly pharmaceutical. "Capital that chases durability goes where the switching cost is," the report states. "In supplements the customer can leave with a purchase order. In sterile injectables the customer cannot leave without a regulatory filing."

## Concentration, testing and the limits of the model

The report treats the testing regime as the layer's one genuine obligation and its hidden cost driver. Under 21 CFR 111.75(a)(1)(i) a manufacturer must verify the identity of any component that is a dietary ingredient before use, per lot, with the exemption route itself benchmarked against 100 per cent identity testing. Finished-batch verification, by contrast, may be performed on *"a subset of finished dietary supplement batches that you identify through a sound statistical sampling plan (or for every finished batch)"* under 111.75(c).

Pheonix Research states its value base as a construct: **USD 31,800.0 million** within a band of **USD 27.5–36.5 billion**, built from disclosed manufacturers' revenue plus a coverage ratio for non-disclosing capacity, and expressed as a share of branded retail value. The report publishes no regional split and no market-share table, because the model carries no geography and no manufacturer discloses a supplement-specific revenue line. Sensitivities are published: holding the realised price at USD 77.18 gives USD 45,150.3 million in 2033 at 4.48 per cent; holding the dose count at 412.0 billion gives USD 34,789.3 million at 1.13 per cent.

The full report, *Global Supplement & Nutraceutical Contract Manufacturing (CDMO) Market Report, Size, Share and Forecast 2026–2033*, is available from Pheonix Research and includes six analytical chapters, the competitive landscape of ten manufacturers, the regulatory analysis for the United States and the European Union, and the investment and risk outlook to 2033.

## About Pheonix Research

Pheonix Research produces market intelligence built from primary and secondary research, combining documentary analysis of regulation and company disclosure with Pheonix's own forecasting models. Its reports state their value bases, their sensitivities and their refusals explicitly.
